Sema is a clinically proven peptide bioregulator used to optimize metabolic health, reduce body fat, and improve performance directly related to biological age and longevity. The molecule has undergone a full cycle of clinical trials, is approved by the FDA and is used in registered medicines Ozempic®, Wegovy® and Rybelsus®.
Sema is a synthetic GLP—1 analog of 31 amino acids with two structural modifications relative to native GLP-1 and a lipid chain attached to Lys26 via spacer, which provides pronounced binding to albumin and prolonged action.
General information
| Features | Values |
|---|---|
| The peptide sequence | His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys[(AEEA)2-ϒ-Glu-N-(17-carboxy-1-oxoheptadecyl)]-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly |
| The molecular formula | C187H291N45O59 |
| Molecular weight | 4113,58 g/mol |
| CAS Number | 910463-68-2 |
| Synonyms | Semaglutide, NN9535, OZEMPIC, RYBELSUS, WEGOVY |
Lyophilized peptides
All peptides undergo lyophilization, a process that is necessary to extend their shelf life, as well as preserve the purity and integrity of the peptides during storage and transportation. Product Usage: This product is intended solely for research purposes. All product information provided on this website is intended for educational purposes.
Product Usage
This product is intended solely for research purposes. All product information provided on this website is intended for educational purposes.
The purity of peptides is more than 99%
Confirmed by certified laboratories. The analysis certificates are available before purchase.
GMR Production Standards
Manufactured in enterprises in accordance with good manufacturing practices. Complete documentation on tracking the origin of the product.
Execution of orders at the highest level
Sending orders the next day at checkout before 12:00 Moscow time. Free standard shipping across the country for orders starting from 15,000₽ (or equivalent).
Without fillers and additives
Only pure active connections. The composition is confirmed by experts for reliable in vitro studies.
Sema is a long—acting synthetic analogue of GLP-1, designed to activate the glucagon-like peptide-1 receptor and prolong the regulation of appetite, insulin secretion, glucose levels and body weight. Due to structural modifications, the molecule is highly resistant to enzymatic degradation and has a long half-life, which allows it to be used in a weekly administration format. The current FDA guidelines describe semaglutide as a long-acting GLP-1 receptor agonist with a half-life of about 1 week. label
Regulation of glucose and insulin secretion
The main research area of semaglutide is related to its effect on carbohydrate metabolism. As a GLP-1 receptor agonist, it enhances glucose-dependent insulin secretion, reduces glucagon secretion, slows down gastric emptying, and reduces postprandial fluctuations in glycemia. That is why semaglutide has become one of the key molecules in the research of type 2 diabetes and metabolic dysregulation. label
Control of body weight and appetite
Semaglutide has been extensively studied in the context of obesity and eating behavior. In the STEP 1 study in obese or overweight adults without diabetes, weekly semaglutide 2.4 mg with lifestyle interventions resulted in an average weight loss of 14.9% by week 68 versus 2.4% in the placebo group. These findings have made semaglutide one of the most significant molecules in long-term weight control research. Once-Weekly Semaglutide in Adults with Overweight or Obesity | New England Journal of Medicine
Cardiometabolic effects
In addition to the effects on weight and glycemia, semaglutide is being actively studied in the context of cardiovascular risk. In the SELECT study, in overweight or obese patients with established cardiovascular disease but without diabetes, semaglutide 2.4 mg reduced the risk of major adverse cardiovascular events compared with placebo. This has significantly expanded the research interest in the molecule beyond just body weight control. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes | New England Journal of Medicine
Liver and metabolic dysfunction
A separate line of research on semaglutide is related to MASH and fatty liver disease. In phase 3, published in 2025, in patients with metabolically associated steatohepatitis and moderate to severe fibrosis, semaglutide 2.4 mg improved liver histological parameters compared with placebo. This makes the molecule important for studying the relationship between incretin therapy, obesity, and ectopic fat accumulation. Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis | New England Journal of Medicine
Pharmacokinetics and research value
Semaglutide is of particular interest as a long-acting GLP-1 agonist with convenient weekly exposure. Such pharmacokinetics allows us to study stable changes in appetite, body weight, glycemia, and cardiometabolic parameters without frequent administration. It is the combination of pronounced clinical activity and long-term action that has made semaglutide one of the basic molecules of modern incretin pharmacology. label
Links
1. FDA. WEGOVY prescribing information, 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215256s024lbl.pdf?utm_source=chatgpt.com
2. FDA. OZEMPIC prescribing information, 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209637s035%2C209637s037lbl.pdf?utm_source=chatgpt.com
3. Wilding J.P.H. et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM, 2021. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
4. Lincoff A.M. et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM, 2023. https://www.nejm.org/doi/full/10.1056/NEJMoa2307563
5. Sanyal A.J. et al. Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis. NEJM, 2025. https://www.nejm.org/doi/full/10.1056/NEJMoa2413258